These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7835805)

  • 1. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer.
    Jacobs I
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S22-7. PubMed ID: 7835805
    [No Abstract]   [Full Text] [Related]  

  • 2. Personalizing ovarian cancer screening.
    Goozner M
    J Natl Cancer Inst; 2010 Aug; 102(15):1112-3. PubMed ID: 20668268
    [No Abstract]   [Full Text] [Related]  

  • 3. Familial ovarian cancer screening.
    Stirling D; Porteous ME; Evans DG; Pichert G; Steel M
    J Clin Oncol; 2006 Feb; 24(6):e11. PubMed ID: 16484689
    [No Abstract]   [Full Text] [Related]  

  • 4. [Screening for ovarian cancers: critical analysis].
    Pennehouat G; Gugliemina JN; Naouri M; Créquat J; Bouret JM; Thébault Y; Madelenat P
    Contracept Fertil Sex; 1993 Mar; 21(3):223-30. PubMed ID: 7951617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A step forward for two-step screening for ovarian cancer.
    Hensley ML
    J Clin Oncol; 2010 May; 28(13):2128-30. PubMed ID: 20368556
    [No Abstract]   [Full Text] [Related]  

  • 6. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
    Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
    J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mass-screening for ovarian cancer].
    Sato S; Higuchi T; Yokoyama Y; Sakamoto T
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():601-4. PubMed ID: 15535316
    [No Abstract]   [Full Text] [Related]  

  • 9. CA-125: a biomarker put to the test.
    Schmidt C
    J Natl Cancer Inst; 2011 Sep; 103(17):1290-1. PubMed ID: 21852262
    [No Abstract]   [Full Text] [Related]  

  • 10. [Expression of CA-125 in ovarian cancer].
    Mircea R; Frîncu DL; Dumitrache F
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1191-4. PubMed ID: 20191897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How appropriate are the american college of radiology appropriateness criteria for ovarian cancer screening.
    Dubinsky TJ
    Ultrasound Q; 2010 Dec; 26(4):225-6. PubMed ID: 21084937
    [No Abstract]   [Full Text] [Related]  

  • 12. Circulating tumour markers in ovarian tumours.
    von Schlippe M; Rustin GJ
    Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer.
    de Bruijn HW; van der Zee AG; Aalders JG
    Curr Opin Obstet Gynecol; 1997 Feb; 9(1):8-13. PubMed ID: 9090475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring ovarian cancer: CA125 trial stirs controversy.
    Chitale R
    J Natl Cancer Inst; 2009 Sep; 101(18):1233-5. PubMed ID: 19738165
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening for ovarian cancer.
    Jacobs I; Oram D
    Biomed Pharmacother; 1988; 42(9):589-96. PubMed ID: 3071382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer screening. American College of Radiology. ACR Appropriateness Criteria.
    Böhm-Vélez M; Mendelson E; Bree R; Finberg H; Fishman EK; Hricak H; Laing F; Sartoris D; Thurmond A; Goldstein S
    Radiology; 2000 Jun; 215 Suppl():861-71. PubMed ID: 11037511
    [No Abstract]   [Full Text] [Related]  

  • 17. Screening and detection of ovarian cancer.
    Breedlove G; Busenhart C
    J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
    Petignat P; Vajda D; Obrist R
    Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
    J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.